Pan-cancer characterization of the pyrimidine catabolic enzyme UPB1 identifies a tumor-suppressive prognostic biomarker in skin cutaneous melanoma.

Yin Men Yi Shao Yong-Feng Chen Ping Wang Yiyang Li Zhen-Zhen Yang Rui-Ting Feng Hui Wang Yin-Sen Song Cong Ding

Jul 2026 · Naunyn-Schmiedeberg's Archives of Pharmacology · 0 citations · 39 references

Medicine

TL;DR

It is suggested that UPB1 functions as a tumor-suppressive factor linked to pyrimidine catabolism and may serve as a prognostic biomarker, particularly in skin cutaneous melanoma (SKCM).

DOI PubMed Semantic Scholar

View source

Similar papers

Open access Jan 2026

Integrative Pan‐Cancer Characterization of lncRNA UPK1A‐AS1 and Its Role in Hypoxia‐Associated Sorafenib Resistance in Hepatocellular Carcinoma

It is suggested that UPK1A-AS1 is a hypoxia‐inducible oncogenic lncRNA that plays dual roles in cancer, with cancer type‐dependent associations with progression and immune modulation across malignancies and mechanistically mediating hypoxia‐associated drug resistance in HCC.

Ze-Kai Li, Min Luo, Shu-Sen Fang et al. · Analytical Cellular Patholog... · 0 citations

Open access Sep 2026

Comprehensive pan-cancer analysis of DIMT1 reveals its prognostic significance and immune-associated characteristics with experimental validation in gastric cancer

Pan-cancer analyses revealed distinct genomic and epigenetic alteration patterns and demonstrated significant associations between DIMT1 expression and immune infiltration profiles, immune regulatory genes, and cancer-type-specific TMB/MSI characteristics in gastric cancer.

S. Liu, Jian Yang, Min Luo · BMC Cancer · 0 citations

Open access Aug 2026

CARS1 as a Prognostic Biomarker and Candidate Therapeutic Vulnerability in Hepatocellular Carcinoma: Insights Into Tumor Progression and the Immune Microenvironment.

BACKGROUND Cysteinyl-tRNA synthetase 1 (CARS1) has been included in ferroptosis-related prognostic signatures, but its clinicopathological relevance, cellular functions, and relationship with the immune microenvironment in hepatocellular carcinoma (HCC) remain incompletely characterized. METHODS Transcriptomic and cl...

Ye-Zhen Tang, Ke-Jun Liu, Zhen-Ya Tan et al. · Frontiers in Bioscience · 0 citations

Open access Sep 2026

SGPP1 as a tumor suppressor in esophageal squamous cell carcinoma: Potential molecular mechanisms involving UGT1A9/UGT2B28 and clinical prognostic significance

SGPP1 functions as a tumor suppressor gene in ESCC and may inhibit tumor progression by regulating UGT1A9/UGT2B28‑mediated metabolic pathways and serve as a prognostic biomarker and a potential therapeutic target in ESCC.

L. Su, L. Hou, Xue-Tao Han et al. · Oncology Report · 0 citations

Open access Sep 2026

Multi-omics and experimental validation reveal ISG20L2 as a potential pro-oncogenic regulator in gastric cancer

ISG20L2 is aberrantly upregulated and associated with malignant biological features and immune-related characteristics in gastric cancer, supporting its potential role as a pro-oncogenic regulator and a candidate molecular indicator requiring further clinical validation.

Song Liang, Chuan-Jun Wang, Yong-Kang Liang et al. · Frontiers in Oncology · 0 citations

Open access Aug 2026

Multi-omics screening and functional validation identify SLC5A6 as a candidate disulfidptosis-related gene and prognostic biomarker in hepatocellular carcinoma

The findings suggest that SLC5A6 may participate in glucose-deprivation-induced disulfide stress, while its direct role in regulating disulfidptotic cell death remains to be established.

Chong Fu, Ze-Min Fang, Yan-Ping Zhang et al. · Frontiers in Oncology · 0 citations